Chromosomal Instability Associated with Improved Outcomes in Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

There is an association between extreme chromosomal instability and improved outcome in estrogen receptor (ER)-negative breast cancers, a new study published online early in the journal Annals of Oncology has shown.

Previous studies have shown that extreme chromosomal instability is associated with improved clinical outcome in patients with ER-negative breast cancer, while it has been shown to be linked with drug resistance and poor outcomes in various other cancers.

For this study, researchers analyzed 1,173 tumors form the breast cancer TACT trial by performing dual centromeric fluorescence in situ hybridization for chromosomes 2 and 15.

Results showed that during a median follow-up of 91 months, extreme chromosomal instability was associated with improved clinical outcome in patients with ER-negative breast cancer (P trend = 0.03). In addition, researchers found that increasing chromosomal instability was associated with improved outcome in patients with ER-negative/HER2-negative breast cancers (P trend = 0.007).

Identifying patients with extreme chromosomal instability may help to predict prognosis and guide treatment decisions.

Chromosomal Instability Associated with Improved Outcomes in Breast Cancer
Association between extreme chromosomal instability and improved outcome in ER-negative breast cancers.
The aim of this current study was to validate this finding using previously defined CIN thresholds in a much larger prospective cohort from a randomised, controlled, clinical trial.
READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters